Dedicated to supporting you on your treatment journey

ARC is a patient support program that offers a range of educational resources to help you

  • Understand your insurance benefits and how they cover Aliqopa treatment
  • Identify sources of financial assistance that may be able to help you with your out-of-pocket costs
  • CALL:

    833-ALIQOPA
    (833-254-7672)
    9 AM-7 PM ET,
    Monday-Friday

    Select:

    Option 1
    for Access Counselors,
    Option 2
    for the Aliqopa $0 Co-Pay Program, or
    Option 3
    for Bayer Medical Information
  • FAX:

    833-4ARCFAX
    (833-427-2329)

If you need help getting your Aliqopa treatment, the ARC program offers:

  • Bayer Patient Assistance Program (free drug) for eligible patients who are uninsured or underinsured and meet certain eligibility criteria*
  • For patients whose coverage is delayed or who experience a temporary lapse in coverage, ARC offers a Temporary Patient Assistance Program that provides free drug during this limited period without coverage
  • Aliqopa $0 Co-Pay Program for eligible patients with insurance through an employer or insurance they have purchased themselves (also known as commercial or private insurance)
  • Referrals to independent assistance foundations that may be able to help patients with government-sponsored insurance (such as Medicare, Medigap, Medicaid, VA/DoD health plans, and TRICARE), or patients who need help with travel expenses related to their treatment§

Financial support may vary based on application criteria, and is subject to change or discontinuation.

*ARC provides Aliqopa free of charge for eligible patients who are uninsured or underinsured. In order to qualify for assistance, you must meet certain eligibility criteria.

You must not be enrolled in a government-sponsored program, and you must meet certain other eligibility criteria to qualify for this program. If approved, you may pay as little as $0, with a maximum benefit of $25,000 per year.

Patients with Medicare or other government insurance who need assistance with cost-share requirements for Aliqopa may be eligible for co-pay or coinsurance assistance through an independent co-pay assistance foundation. Access Counselors can verify your coverage for Aliqopa. If co-pay assistance needs are identified, the Access Counselor can provide information about any available foundations. The foundation will determine your eligibility for co-pay or coinsurance assistance based on their own criteria, and will contact you directly regarding the application process.

§Patients may be eligible for travel assistance through an independent travel assistance foundation. Access Counselors can provide information about any available foundations. The foundation will determine your eligibility for travel and other supporting assistance based on their own criteria, and will contact you directly regarding the application process.

What is ALIQOPA?

ALIQOPA is a prescription medicine used to treat adults with follicular lymphoma (FL) when the disease has come back after treatment with at least two prior medicines.

Aliqopa went through a faster FDA approval process because of how it caused FL tumors to shrink. Data gathered from an additional trial may be needed for continued approval of its current use.

It is not known if ALIQOPA is safe and effective in children.

Important Safety Information

ALIQOPA can cause serious side effects, including:
Infections: ALIQOPA can cause serious infections that may lead to death. The most common serious infection was pneumonia. Tell your healthcare provider right away if you have a fever or any signs of an infection during treatment with ALIQOPA.

High blood sugar (hyperglycemia): High blood sugar is common following ALIQOPA infusion and can sometimes be serious. Tell your healthcare provider if you develop any symptoms of hyperglycemia during treatment with ALIQOPA. Symptoms of hyperglycemia may include being very hungry, being very thirsty, frequent urination and headaches.

High blood pressure (hypertension): High blood pressure is common following ALIQOPA infusion and can sometimes be serious.

Lung or breathing problems: Your healthcare provider may do tests to check your lungs if you have breathing problems during treatment with ALIQOPA. Tell your healthcare provider right away if you develop new or worsening cough, shortness of breath, or difficulty breathing.

Low white blood cell count (neutropenia): Neutropenia is common with ALIQOPA treatment and can sometimes be serious. Your healthcare provider will check your blood counts regularly during treatment with ALIQOPA. Tell your healthcare provider right away if you have a fever or any signs of infection during treatment with ALIQOPA.

Severe skin reactions: Skin peeling, rash, and itching are common with ALIQOPA and can sometimes be serious. Tell your healthcare provider if you develop skin peeling, itching, or rash during treatment with ALIQOPA. Your healthcare provider may withhold treatment, decrease your dose, or permanently stop treatment if you develop severe skin reactions during treatment with ALIQOPA.

Before receiving ALIQOPA, tell your healthcare provider about all of your medical conditions, including if you:

  • have an infection
  • have lung or breathing problems
  • have high blood pressure (hypertension)
  • have diabetes or high blood sugar (hyperglycemia)
  • are pregnant or plan to become pregnant. ALIQOPA can harm your unborn baby.
    • Your healthcare provider will perform a pregnancy test before starting treatment with ALIQOPA.
    • Females who are able to become pregnant should use effective birth control (contraception) during treatment with ALIQOPA and for at least 1 month after the last dose of ALIQOPA. Talk to your healthcare provider about birth control methods that may be right for you. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with ALIQOPA.
    • Males with female partners who are able to become pregnant should use effective birth control (contraception) during treatment with ALIQOPA and for at least 1 month after the last dose of ALIQOPA.
  • are breastfeeding or plan to breastfeed. It is not known if ALIQOPA passes into your breast milk. Do not breastfeed during treatment with ALIQOPA and for at least 1 month after the last dose of ALIQOPA. Talk to your healthcare provider about the best way to feed your child during treatment with ALIQOPA.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain other medicines may affect how ALIQOPA works.

Know the medicines you take. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.

What should I avoid while receiving ALIQOPA?

  • Avoid taking St. John’s Wort during treatment with ALIQOPA.
  • Avoid drinking grapefruit juice during treatment with ALIQOPA.

The most common side effects of ALIQOPA include:

  • low white blood cell count (leukopenia)
  • low platelets in your blood (thrombocytopenia)
  • diarrhea
  • decreased strength and tiredness
  • lower respiratory tract infection
  • nausea

These are not all of the possible side effects of ALIQOPA. Call your doctor for medical advice about side effects.

For important risk and use information about Aliqopa, please see the full Prescribing Information.

You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.
For Bayer products, you can report these directly to Bayer by clicking here.

ATTENTION

You are now leaving the AliqopaTM (copanlisib) website.
Bayer is not responsible for the content presented by any independent website, including any advertising claims, special offers, illustrations, names, or endorsements. Thank you for visiting Aliqopa.

ATTENTION

You are now leaving the Aliqopa website.
Bayer is not responsible for the content presented by any independent website, including any advertising claims, special offers, illustrations, names, or endorsements.
Thank you for visiting Aliqopa.

ATTENTION

You are now leaving the Aliqopa website.
Bayer is not responsible for the content presented by any independent website, including any advertising claims, special offers, illustrations, names, or endorsements.
Thank you for visiting Aliqopa.

ATTENTION

You are now leaving the Aliqopa website.
Bayer is not responsible for the content presented by any independent website, including any advertising claims, special offers, illustrations, names, or endorsements.
Thank you for visiting Aliqopa.

For information and tips on how to get the most out of your treatment with Aliqopa, please download the Aliqopa Patient Brochure.